nct_id: NCT05123482
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2021-11-17'
study_start_date: '2021-10-18'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)'
  - drug_name: 'Drug: AZD8205 in combination with AZD9574'
  - drug_name: 'Drug: AZD8205 and AZD5305 (saruparib)'
  - drug_name: 'Drug: AZD8205 and AZD2936 (Rilvegostomig)'
  - drug_name: 'Drug: AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)'
  - drug_name: 'Drug: AZD8205'
long_title: A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation
  and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer
  Agents in Participants With Advanced Solid Tumors (BLUESTAR)
last_updated: '2025-11-03'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: AstraZeneca
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 370
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- "* Age \u2265 18 years"
- '* Relapsed/metastatic solid tumors treated with prior adequate standard of care
  therapy for tumor type and stage of disease or where in the opinion of the Investigator,
  a clinical trial is the best option for the next treatment based on response and/or
  tolerability to prior therapy.'
- '* Measurable disease per RECIST v1.1'
- '* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1'
- "* Life expectancy \u2265 12 weeks"
- '* Adequate bone marrow, hepatic, and renal function as defined in the protocol'
- 'Additional Inclusion Criteria For Sub-Study 1 Part A:'
- "\u2022 Histologically or cytologically confirmed metastatic or locally advanced/recurrent\
  \ breast cancer, ovarian cancer, BTC or endometrial cancer"
- 'Additional Inclusion Criteria For Sub-Study 1 Part B:'
- '* Histologically or cytologically confirmed metastatic or locally advanced and
  recurrent disease for the respective cohort:'
- 1. Cohort B1 (Biliary Tract Cancer)
- 2. Cohort B2 (Ovarian Cancer)
- 3. Cohort B3 (Breast Cancer)
- 4. Cohort B4 (Endometrial Cancer)
- 5. Cohort B5 (Squamous Non-Small Cell Lung Cancer)
- 'Additional Inclusion Criteria For Sub-Study 2 Part A:'
- "* Minimum body weight \u2265 30 kg."
- '* Histologically or cytologically confirmed metastatic or locally advanced/recurrent
  breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell
  lung cancer.'
- 'Additional Inclusion Criteria For Sub-Study 3 Part A:'
- "* Minimum body weight \u2265 30 kg (for participants enrolled in cohorts including\
  \ rilvegostomig only)."
- '* Histologically or cytologically confirmed metastatic or locally advanced/recurrent
  breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell
  lung cancer.'
- 'Additional Inclusion Criteria For Sub-Study 4 Part A:'
- "* Minimum body weight \u2265 30 kg (for participants enrolled in cohorts including\
  \ rilvegostomig only)."
- '* Histologically or cytologically confirmed metastatic or locally advanced/recurrent
  breast cancer, endometrial cancer or squamous non-small cell lung cancer.'
- '* Participants must have progressed following at least one but no more than 3 prior
  lines of treatment for metastatic or relapsed disease and have no satisfactory alternative
  treatment option as judged by the Investigator.'
- 'Exclude - Key Exclusion Criteria:'
- 'Exclude - * Treatment with any of the following:'
- Exclude - 1. Nitrosourea or mitomycin C within 6 weeks prior to the first dose of
  study treatment
- Exclude - 2. Any investigational agents or study drugs from a previous clinical
  study within 5 half-lives or 28 days (whichever is shorter) prior to the first dose
  of study treatment
- 'Exclude - 3. Any other anticancer treatment within the following time periods prior
  to the first dose of study intervention:'
- 'Exclude - 1. Cytotoxic treatment: 21 days'
- 'Exclude - 2. Non-cytotoxic drugs: 21 days or 5 half-lives (whichever is shorter)'
- 'Exclude - 3. Biological products including immuno-oncology agents: 28 days'
- Exclude - * Spinal cord compression or a history of leptomeningeal carcinomatosis.
- Exclude - * Brain metastases unless treated, asymptomatic, stable, and not requiring
  continuous corticosteroids at a dose of \> 10 mg prednisone/day or equivalent for
  at least 4 weeks prior to start of study.
- Exclude - * Active infection including tuberculosis and HBV, HCV or HIV
- Exclude - * History of (non-infectious) ILD/pneumonitis that required steroids,
  has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled
  out by imaging at screening.
- Exclude - * Clinically severe pulmonary compromise resulting from intercurrent pulmonary
  illnesses
- 'Exclude - * Participants with any of the following cardiac criteria:'
- Exclude - 1. History of arrhythmia which is symptomatic or requires treatment (NCI
  CTCAE v5.0 Grade 3); symptomatic or uncontrolled atrial fibrillation, or asymptomatic
  sustained ventricular tachycardia.
- Exclude - 2. Uncontrolled hypertension.
- Exclude - 3. Acute coronary syndrome/acute myocardial infarction, unstable angina
  pectoris, coronary intervention procedure with percutaneous coronary intervention,
  or coronary artery bypass grafting within 6 months.
- Exclude - 4. History of brain perfusion problems (eg, carotid stenosis) or stroke,
  or transient ischemic attack in the last 6 months prior to screening.
- "Exclude - 5. Symptomatic heart failure (NYHA class \u2265 2)."
- Exclude - 6. Prior or current cardiomyopathy.
- Exclude - 7. Severe valvular heart disease.
- Exclude - 8. Mean resting QTcF \> 470 msec.
- Exclude - 9. Risk factors for QTc prolongation or risk of arrhythmic events such
  as heart failure, congenital long QT syndrome, family history of long QT syndrome
  or unexplained sudden death under 40 years of age.
- Exclude - * Patients with history of myelodysplastic syndrome (MDS)/acute myeloid
  leukemia (AML) or with features suggestive of MDS/AML (as determined by prior diagnostic
  investigation)
- 'Exclude - Additional Exclusion Criteria For Sub-Study 2 Part A:'
- Exclude - * Thromboembolic event within 3 months before the first dose of study
  intervention - No longer applicable per amendment 7
- Exclude - * Experienced a toxicity that led to permanent discontinuation of prior
  immunotherapy.
- Exclude - * Active or prior documented autoimmune or inflammatory disorders requiring
  chronic treatment with steroids or other immunosuppressive treatment.
- Exclude - * History of organ transplant
- Exclude - Additional Exclusion Criteria For Sub-Study 2 Part B
- "Exclude - \u2022 Previous treatment with any therapy that contains a TOP1i (eg.\
  \ irinotecan, topotecan, trastuzumab deruxtecan, etc.)"
- 'Exclude - Additional Exclusion Criteria For Sub-Study 3 Part A:'
- Exclude - * Concomitant use of medications or herbal supplements known to be strong
  cytochrome P (CYP) 3A4 inducers/inhibitors.
- Exclude - * Any history of persisting (\> 2 weeks) severe cytopenia due to any cause
- Exclude - * Patients with any known predisposition to bleeding
- Exclude - * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability
  to swallow the formulated product or previous significant bowel resection that would
  preclude adequate absorption of saruparib.
- Exclude - * Previous treatment with any therapy that contains a TOP1i (eg. irinotecan,
  topotecan, trastuzumab deruxtecan, etc.)
- 'Exclude - Additional Exclusion Criteria For Sub-Study 4 Part A:'
- Exclude - * Patients have received prior therapy with AZD9574 or more than 1 prior
  line of any other PARPi-based regimen
- Exclude - * Concomitant use of medications or herbal supplements known to be strong
  cytochrome P (CYP) 3A4 inducers/inhibitors.
- Exclude - * Previous treatment with rilvegostomig for the cohort treated with rilvegostomig
- Exclude - * Previous treatment with any therapy that contains a TOP1i (eg. irinotecan,
  topotecan, trastuzumab deruxtecan, etc.)
- Exclude - * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability
  to swallow the formulated product or previous significant bowel resection that would
  preclude adequate absorption of AZD9574
short_title: A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer
  Drugs, in Participants With Advanced or Metastatic Solid Malignancies
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This research study is studying a new compound, AZD8205, as a possible treatment
  for advanced or metastatic solid tumours alone or in combination with anti-cancer
  agents
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Sub-Study 1 AZD8205 Monotherapy
      arm_internal_id: 0
      arm_description: 'Sub-Study 1 has two parts:


        Part A : The aim is to determine the safety, tolerability, Recommended Phase
        2 Dose (RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205.


        Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205
        as monotherapy in select solid tumors.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD8205'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Sub Study 2: AZD8205 in combination with rilvegostomig'
      arm_internal_id: 1
      arm_description: 'Sub-Study 2 has two parts:


        Part A : Dose escalation to determine the safety, tolerability of AZD8205
        + rilvegostomig Part B: Dose expansion to evaluate anti-tumor activity of
        AZD8205 + rilvegostomig in select solid tumors.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD8205 and AZD2936 (Rilvegostomig)'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Sub-Study 3 AZD8205 in combination with saruparib, with or without
        rilvegostomig
      arm_internal_id: 2
      arm_description: 'Sub-Study 3 has two parts:


        Part A : Dose escalation to determine the safety, tolerability of AZD8205
        + saruparib. Rilvegostomig may be added in a triplet combination once an AZD8205
        + saruparib combination dose/schedule has been considered safe.


        Part B: Dose expansion to evaluate anti-tumor activity of AZD8205 + saruparib
        with or without rilvegostomig in select solid tumors.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD8205 and AZD5305 (saruparib)'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Sub-Study 4: AZD8205 in combination with AZD9574 with or without
        rilvegostomig (AZD2936)'
      arm_internal_id: 3
      arm_description: 'Sub-Study 4 has two parts:


        Part A : Dose escalation to determine the safety, tolerability of AZD8205
        + AZD9574. Rilvegostomig may be added in a triplet combination once an AZD8205
        + AZD9574 combination dose/schedule has been considered safe.


        Part B: may be added in the future depending on emerging data, following a
        formal protocol amendment.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD8205 in combination with AZD9574'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: AZD8205 in combination with AZD9574 plus rilvegostomig
          (AZD2936)'
        level_internal_id: 1
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Ovarian Cancer, Other
        - clinical:
            oncotree_primary_diagnosis: Intraductal Papillary Neoplasm of the Bile
              Duct
        - clinical:
            oncotree_primary_diagnosis: Endometrial Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Invasive Breast Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Intracholecystic Papillary Neoplasm
        - clinical:
            oncotree_primary_diagnosis: Breast Neoplasm, NOS
        - clinical:
            oncotree_primary_diagnosis: Non-Small Cell Lung Cancer
        - clinical:
            oncotree_primary_diagnosis: Ovarian Epithelial Tumor
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Metastatic
          - Locally Advanced
          - Recurrent
